US Neurology Editorial Board member, David Hafler (Yale School of Medicine, Connecticut, USA) talks to us about his exciting latest research looking at regulatory T cell RNA sequencing in multiple sclerosis (MS), as well as other potential therapeutic targets.
1. What are the major gaps in our understanding of the processes underlying multiple sclerosis (MS)? (0:04)
2. How has the identification of genetic variants enhanced our understanding of MS? (1:30)
3. Could you tell us a little about your research using single-cell RNA sequencing in MS? (3:30)
4. How do environmental factors such as salt and fat contribute to regulatory T cell dysfunction in MS? (6:12)
5. What is the potential of the NF-kappaB pathway and other transcription factors as therapeutic targets in MS? (7:25)
Speaker disclosures: David Hafler has received funding from Bristol-Myers Squibb, Novartis and Genentech; he has been a consultant for Compass Therapeutics, EMD Serono, Novartis Pharmaceuticals, Sanofi Genzyme, Versant Venture, Genentech and Proclara Bioscience.
Filmed at the American Academy of Neurology (AAN) Annual Meeting, Philadelphia, USA, May 2019.
Share this Video
Related Videos In Neuroimmunology
Sean Pittock, EAN 2020 – Phase 3 PREVENT Study Insights in Neuromyelitis Optica Spectrum Disorder
Sean Pittock (Mayo Clinic College of Medicine, Rochester, MN, USA) shared with us his expert insights from the phase 3 PREVENT study, a randomized controlled trial of eculizumab in AQP4 antibody-positive participants with neuromyelitis optica (ClinicalTrials.gov Identifier: NCT01892345), including a sub analysis he presented on eculizumab monotherapy. Questions 1. Could you give us an overview […]
Celia Oreja-Guevara, EAN 2020 – Regional Findings From The Phase 3 PREVENT Study in NMOSD
Great to have an opportunity to speak with Celia Oreja-Guevara (University Hospital San Carlos and University Complutense, Madrid, Spain) around the highlights of her presentation entitled: Regional outcomes of eculizumab treatment in patients with aquaporin-4 immunoglobin G-positive neuromyelitis optica spectrum disorder: findings from the phase 3 PREVENT study (ClinicalTrials.gov Identifier: NCT01892345). Questions 1. What were […]
Angela Vincent, MDS 2019 – Autoimmune movement disorders
It was an absolute pleasure to meet with Angela Vincent, Emeritus Professor of Neuroimmunology at the University of Oxford. Until 2016 she led the clinical and research laboratory at Oxford specialising in antibody-mediated neurological diseases. Despite not being a neurologist herself, she spoke from long experience of helping to identify and characterise pathogenic antibodies in […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!